PA-SYNERGIS-SOFTWARE
24.3.2022 13:23:11 CET | Business Wire | Press release
Synergis Software , a global leader in engineering document management and workflow solutions, announced today that Synergis Adept was named as a Leader in the Enterprise Content Management and Product Data Management categories in the G2 Spring 2022 Grid® Reports. G2 is a peer-to-peer business software review website that helps companies choose the best tools for their business. Products in the Leader quadrant are rated highly by verified users of the software product and have significant market presence scores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005238/en/
According to G2’s 2022 Spring Reports, Adept software earned 18 G2 Badges with top placements for “Best Usability”, “Fastest Implementation”, “Ease of Setup”, “Ease of Admin”, and “Highest User Adoption”, and grade the company as “Easiest to do Business With” and “Best Support”—recognition Synergis has received consistently over the past seven quarters.
“These achievements reflect the experience we deliver with our software and the relationships we build with some of the world’s best companies,” says Scott Lamond, vice president of marketing at Synergis Software. “Delivering value in ways that are meaningful to our customers is our top priority, so the G2 results really matter to us. Our customers range from small to very large across varied industries , and they’re all part of the Synergis family. We’re grateful for their trust and inspired to bring them even greater value as we grow together.”
G2 highlights the value of Adept engineering document management software across three categories: Enterprise Content Management, Product Data Management, and Construction Drawing Management. G2 Spring 2022 badges include:
- Leader Enterprise Content Management (ECM)
- Leader Product Data Management (PDM)
- Momentum Leader Enterprise Content Management (ECM)
- Momentum Leader Product Data Management (PDM)
- High Performer Mid-Market Enterprise Content Management (ECM)
- High Performer Mid-Market Product Data Management (PDM)
- High Performer Construction Management
- High Performer Construction Drawing Management
- Best Relationship
- Best Support
- Best Support Small-Business
- Easiest To Do Business With Mid-Market
- Easiest To Do Business With
- Easiest To Do Business With Small-Business
- Fastest Implementation
- Highest User Adoption
- Most Implementable
- Best Usability
The G2 reports are based on direct customer feedback combined with G2’s unique algorithm that calculates customer satisfaction and market presence scores in real-time.
For more details about Adept in the G2 Spring 2022 Reports, visit our website .
Quotes from Verified Users about Synergis Adept
“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites."
Teresa Yang, Product Manager, Document Management, Dow Chemical
“No other software company anywhere works as closely with their customers. The staff is incredibly responsive and consistently goes above and beyond to solve customer issues. For a system your business cannot operate without, this is invaluable.”
Ryan Mongeau, Director of Technology, Space Age Electronics
“Adept has improved our efficiency/processes by 200%. What once took hours in the old systems, I can do in minutes. It’s a very powerful system with unlimited possibilities for adding more useful information for future projects. And the Helpdesk team can tackle and/or resolve any issue I bring to them to improve or streamline our processes.”
Milias H, The Folger Company, Document Control Service Provider
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects your enterprise applications so your data and business processes flow seamlessly across your entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, our commitment to clients is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded.
Adept has been battle tested by engineers for over 30 years with customers such as Dow Chemical, Con Edison, General Mills, Merck, NASA, and Nucor Steel.
About G2 Crowd
G2 is the world’s largest tech marketplace where businesses can discover, review, and manage the technology they need to reach their potential. Today, more than 3M people visit G2 to read and write authentic reviews about thousands of software products and professional services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005238/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom